Naslov
Amantadine, a glutamate antagonist, potentates levodopa-induced improvement in parkinsonian patients after acute and/or chronic treatment
(Levodopa-induced improvement in parkinsonian patients after acute and/or chronic treatment)

Autori
Relja, Maja ; Koršić, Marta

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Journal Neural Transmission / Carlsson, Arvid - Beč : Springer, 2000, XXXIII-XXXIII

Skup
5th Congress European Society for Clinical Neuropharmacology

Mjesto i datum
Opatija, Hrvatska, 17.05.2000. - 21.05.2000

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Amantadine; glutamate; levodopa; Parkinson's disease

Sažetak
When amantadine was first used as prophylaxis for influenza incidental improvement in Parkinson's disease (PD) was observed. Consequentky, amantadine is among the few NMDA antagonist that have been available for clinical use for many years. Because the drug is belived to lose its benefit after several months of regular use, it is often discontinued during second year of treatment. To determine whether co-administration of amantadine with levodopa might potentiate clinical improvement of levodopa during chronic treatment we investigated both "denovo" PD patients and patients who have been on levodopa and amantadine combination therapy for 12-15 months. After an individual morning dose of levodopa (+carbidopa), amantadine (100 mg) and/or combination therapy (levodopa/carbidopa + amantadine) motor response was assesed in PD patients at 30 minutes intervals, using UPDRS score and instrumental rigidity measurements (Relja et al. 1996 Clin Neuropharmacol 19:148). Motor response was assesed in 10 "de novo" patients (age range 41-63 years) and in 18 patients (age range 57-74 yearts, disease duration 2-7 years) who has been on levodopa/amantadine combination therapy for at least 12 month ( all medication has been omitted 24-28 hours before testing) While levodopa treatment significantly improved motor performance in both "de novo" and chronic PD patients (p<0.001), amantadine monotherapy had only a slight effect. However, amantadine significantly potentate effect of levodopa (p<0.01) both in "de novo" and in patients on chronic combination therapy (levodopa + amantadine). In conclusion, our results suggest that amantadine might potentate the levodopa therapy even in patients during long-term treatment. Thus, a combination therapy may be reasonable in chronic PD patients.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA